Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Three Amigos Stock Thread -- Ignore unavailable to you. Want to Upgrade?

To: Ken W who wrote (17586)	11/29/1999 9:09:00 PM
From: Sal D	Read Replies (2) \| Respond to of 29382

Ken, How you doing, I looked at the Bloomberg report. Drug companies are very unpredictable as you know,they all seem to be one approval away from hitting it big and one failure away from going under. But anyway one I liked was Cor Therapeutics (COOR) they develop pharmaceutical products for the treatment and prevention of severe cardiovascular diseases. All of there products are undergoing development or regulatory review. It's leading candidate is Integrilin, it is a small synthetic peptide that prevents platelet aggregation. It is intended for patients with various heart diseases, including angina,NQMI,and ST segment elevation (very promising). They are also conducting clinical trials for an oral platelet aggregation inhibitor, which may be used to prevent heart disease and stroke. In May they signed a product discovery and pharmacogenomics agreement with CuraGen Corp. valued at $2.6 million for an initial period of 18 months. In July they received a $12 million milestone payment from Schering-Plough. I don't know if they have anything up there sleeve for the conference, but they will be there. I still think Sergio has the right idea with a bioteck fund, spreads the risk out. But if I was going to go with one COOR would be it. Anyone interested could check this one out. Joe P.S. I see your now on the other side of AOL.